Browse the corpus

Docetaxel, in combination with cisplatin, is approved by the Federal Drug Agency (FDA) as a first-line treatment for prostate cancer and is the standard of care for castration-resistant prostate cancer. The medication is effective in non–small cell lung cancer (NSCLC), particularly for patients with poor prognosis or metastatic disease, and is a standard adjunct in breast cancer treatment. Additionally, docetaxel is part of the TEX regimen for advanced gastric cancer and can be considered for stage IV NSCLC after previous therapies. This activity focuses on the indications, mechanism of action, and administration of docetaxel. Participating clinicians are equipped to identify adverse drug reactions, clinical monitoring, pharmacokinetics, drug interactions, toxicity, contraindications, and FDA-issued box warnings. An interprofessional team, including oncologists, pharmacists, and nursing staff, is crucial for optimizing cancer treatment outcomes with docetaxel. Effective patient-centered care requires coordination, communication, and collaboration to manage adverse events, monitor progress, and provide comprehensive patient education. Objectives: Evaluate the mechanism of action of docetaxel to consider symptoms and signs of toxicity. Identify the indications for docetaxel based on patient history, physical exam, and progression of cancer. Assess the adverse effects of docetaxel within a multidrug regimen. Implement effective communication among interprofessional team members to improve treatment efficacy for patients who benefit from docetaxel. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose Dose-dependent pulmonary toxicity has correlations with the administration of docetaxel. Acute bilateral interstitial pneumonitis has been demonstrated to occur during, immediately, and after the initial administration of the drug. Symptoms include dyspnea on exertion, a dry cough, fever, and malaise. The mechanism of action underlying this pulmonary toxicity is poorly understood, but the belief is that an immune-mediated reaction occurs. In treating this toxicity, supportive care is usually sufficient to return patients to their baseline lung function. However, in patients showing clinical signs of either oxygen desaturation or possible respiratory failure, an empiric trial of glucocorticoids has proven effective in relieving pneumonitis.[12] Management of Overdose No known antidote exists for docetaxel overdose. Anticipated complications comprise bone marrow suppression, peripheral neurotoxicity, and mucositis. Granulocyte colony-stimulating factor (G-CSF) administration and symptomatic treatment are recommended. G-CSF significantly reduces the risk of febrile neutropenia.[28]

A broad range of clinical expertise plays a role in cancer treatment. Medical oncologists, radiation oncologists, specialists of involved systems (ie, urologists in prostate cancer), and supporting staff all play a role in optimizing treatments and outcomes based on patients’ needs and wishes. Proper monitoring, managing adverse events and acquired comorbidities, counseling, and education on the treatment options can be considered interprofessional responsibilities. An oncology-specialized pharmacist should be part of the treatment team to verify dosing and potential drug interactions, along with oncology-trained nursing staff trained in administering chemotherapy agents and possible adverse effects. Delivering patient-centered care requires coordination and correspondence between multiple care disciplines. An interprofessional team approach and open communication between clinicians (MD, DO, NP, PA), pharmacists, specialists, nurses, and specialists are necessary to optimize patient outcomes with docetaxel therapy.[29]